Revolution Medicines (RVMD) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Revolution Medicines (NASDAQ: RVMD) in the last few weeks:

• 5/14/2025 – Revolution Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock, down previously from $73.00.
• 5/8/2025 – Revolution Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $67.00 price target on the stock.
• 5/8/2025 – Revolution Medicines had its price target raised by analysts at Oppenheimer Holdings Inc. from $70.00 to $75.00. They now have an “outperform” rating on the stock.
• 5/8/2025 – Revolution Medicines had its price target lowered by analysts at Guggenheim from $87.00 to $80.00. They now have a “buy” rating on the stock.
• 5/8/2025 – Revolution Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $57.00 price target on the stock.
• 4/28/2025 – Revolution Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $67.00 price target on the stock.
• 4/8/2025 – Revolution Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $59.00 price target on the stock.
• 4/1/2025 – Revolution Medicines had its price target lowered by analysts at Stifel Nicolaus from $78.00 to $64.00. They now have a “buy” rating on the stock.

Revolution Medicines Stock Up 1.6%

RVMD traded up $0.64 during midday trading on Tuesday, hitting $40.57. 341,340 shares of the company were exchanged, compared to its average volume of 1,605,258. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $62.40. The firm’s 50 day moving average price is $37.50 and its 200-day moving average price is $42.94. The firm has a market capitalization of $7.56 billion, a P/E ratio of -11.30 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same quarter last year, the firm earned ($0.70) earnings per share. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now directly owns 153,533 shares of the company’s stock, valued at approximately $5,993,928.32. This trade represents a 1.95% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,660 shares of company stock valued at $650,406. Corporate insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

A number of large investors have recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new position in shares of Revolution Medicines during the fourth quarter valued at approximately $34,000. Banque Transatlantique SA bought a new stake in shares of Revolution Medicines in the 1st quarter worth approximately $42,000. Quarry LP purchased a new position in shares of Revolution Medicines in the 1st quarter worth about $50,000. Twin Tree Management LP bought a new position in shares of Revolution Medicines in the first quarter worth approximately $58,000. Finally, Sterling Capital Management LLC raised its stake in shares of Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after purchasing an additional 1,672 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.